


## Supplementary Figure 1


6 days after 5<sup>th</sup> 4D5 administration



### Supplementary Figure 1

Mice with sizeable tumors had reduced levels of circulating 4D5. Each point represents serum anti-HER-2 IgG as a function of tumor volume, six days after the fifth administration of 4D5. Note that mice without detectable tumors at this time point include both mice that subsequently developed progressive tumors and mice that never developed tumors.

## Supplementary Figure 2



### Supplementary Figure 2

Graphs show HER-2 expression profiles determined by flow cytometry of three representative tumors from Untreated, Isotype Control, and ES2B-C001 treatment groups. To perform cytofluorometric analysis, tumors were mechanically dissociated and briefly incubated using 0.05% trypsin-EDTA (Thermo Fisher Scientific) to yield a single-cell suspension. Tumors were incubated with the mouse anti-human HER-2 monoclonal antibody MGR2 (Enzo Life Sciences, Farmingdale, NY, USA), followed by an anti-mouse IgG labeled with Alexa Fluor 488 (IgG-AF488, Thermo Fisher Scientific). Each graph reports two profiles: non-labelled cells (striped profile) and MGR2 (gray profile). HER-2 Median Fluorescence Intensity (MFI) values (normalized on the non-labeled cells samples) were as follows: Untreated, 199; Isotype, 281; ES2B-C001, 280.